Tempus Ai, Inc. shares rise 7.57% intraday after Q2 earnings report shows 89.6% revenue growth and FDA approval for AI ECG software.

Tempus AI, Inc. surged 7.57% intraday, following the release of its Q2 financial report, which showed an 89.6% year-over-year increase in revenue to $314.6 million, a narrowing of net loss, and an upward revision of the full-year revenue guidance to approximately $12.6 billion. The company's genomics division revenue grew 115% year-over-year to $241.8 million, and data services revenue increased 35.7% to approximately $73 million, highlighting strong performance in the precision medicine field. Additionally, the company's AI ECG low ejection fraction software received FDA 510(k) clearance on July 16, 2025, expanding its clinical AI innovation applications.